Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Canagliflozin as an initial therapy in subjects with type 2 diabetes mellitus and to assess the effects of Atherogenic lipids in its glycemic control.

Trial Profile

Canagliflozin as an initial therapy in subjects with type 2 diabetes mellitus and to assess the effects of Atherogenic lipids in its glycemic control.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Oct 2019 Results investigating the regulation of serum uric acid (SUA) levels with canagliflozin in relation to diabetic parameters published in the International Journal of Clinical Pharmacology and Therapeutics
    • 21 Mar 2017 Primary endpoint (changes in HbA1c levels from baseline to 3 months) has been met as per results published in the Drugs in R and D
    • 21 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top